Literature DB >> 24685637

Brain region-specific monoaminergic correlates of neuropsychiatric symptoms in Alzheimer's disease.

Yannick Vermeiren1, Debby Van Dam1, Tony Aerts1, Sebastiaan Engelborghs2, Peter P De Deyn3.   

Abstract

Neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) are present during the disease course of nearly all AD patients and consist of psychosis, agitation/aggression, and depression, among others. Given their detrimental consequences regarding life expectancy, cognition, and socio-economic costs, it is essential to elucidate their neurochemical etiology to facilitate the development of novel and effective pharmacotherapeutics. This study attempted to identify brain region-specific monoaminergic correlates of NPS by measuring the levels of eight monoamines and metabolites in nine relevant postmortem brain regions of 40 behaviorally characterized AD patients, i.e., dopamine (DA), serotonin (5-HT), (nor)epinephrine and their respective metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid, 5-hydroxy-3-indoleacetic acid (5-HIAA), and 3-methoxy-4-hydroxyphenylglycol (MHPG), using RP-HPLC-ECD. Likewise, Mini-Mental State Examination (MMSE) score correlates of monoaminergic neurotransmitter alterations were calculated. As a result, MMSE scores, used as a measure of dementia severity, correlated positively with hippocampal 5-HIAA levels as well as with 5-HT levels of the superior temporal gyrus and cerebellar cortex. Furthermore, hippocampal 5-HIAA levels inversely correlated with agitation scores, whereas thalamic MHPG levels comparably did with the presence of hallucinations. Finally, in the cerebellar cortex, DOPAC/DA ratios, indicative of DA turnover, correlated with physically agitated behavior while MHPG levels correlated with affective disturbances. These findings support the assumption that specific NPS features in AD might be (in)directly related to brain region-specific monoaminergic neurotransmitter alterations. Additionally, the effect of AD pathology on neurochemical alterations in the cerebellum requires further examination due to its important but underestimated role in the neurochemical pathophysiology of NPS in AD.

Entities:  

Keywords:  Alzheimer's disease; behavior; brain tissue; correlations; dementia; monoamines and metabolites; neurochemistry; neuropsychiatric symptoms

Mesh:

Substances:

Year:  2014        PMID: 24685637     DOI: 10.3233/JAD-140309

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  18 in total

Review 1.  Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease.

Authors:  Celina S Liu; Sarah A Chau; Myuri Ruthirakuhan; Krista L Lanctôt; Nathan Herrmann
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

2.  Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid.

Authors:  Victor Bloniecki; Dag Aarsland; Kaj Blennow; Jeffrey Cummings; Farshad Falahati; Bengt Winblad; Yvonne Freund-Levi
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 3.  Neuropsychiatric symptoms in Alzheimer's disease: What might be associated brain circuits?

Authors:  Paul B Rosenberg; Milap A Nowrangi; Constantine G Lyketsos
Journal:  Mol Aspects Med       Date:  2015-06-03

Review 4.  Resistance, vulnerability and resilience: A review of the cognitive cerebellum in aging and neurodegenerative diseases.

Authors:  Katharine J Liang; Erik S Carlson
Journal:  Neurobiol Learn Mem       Date:  2019-01-07       Impact factor: 2.877

5.  Glutamate and GABA-metabolizing enzymes in post-mortem cerebellum in Alzheimer's disease: phosphate-activated glutaminase and glutamic acid decarboxylase.

Authors:  G Sh Burbaeva; I S Boksha; E B Tereshkina; O K Savushkina; T A Prokhorova; E A Vorobyeva
Journal:  Cerebellum       Date:  2014-10       Impact factor: 3.847

6.  Intravoxel incoherent motion diffusion-weighted imaging in the characterization of Alzheimer's disease.

Authors:  Nengzhi Xia; Yanxuan Li; Yingnan Xue; Weikang Li; Zhenhua Zhang; Caiyun Wen; Jiance Li; Qiong Ye
Journal:  Brain Imaging Behav       Date:  2021-09-04       Impact factor: 3.978

7.  Association of locus coeruleus integrity with Braak stage and neuropsychiatric symptom severity in Alzheimer's disease.

Authors:  Clifford M Cassidy; Joseph Therriault; Tharick A Pascoal; Victoria Cheung; Melissa Savard; Lauri Tuominen; Mira Chamoun; Adelina McCall; Seyda Celebi; Firoza Lussier; Gassan Massarweh; Jean-Paul Soucy; David Weinshenker; Christine Tardif; Zahinoor Ismail; Serge Gauthier; Pedro Rosa-Neto
Journal:  Neuropsychopharmacology       Date:  2022-02-17       Impact factor: 8.294

8.  Alzheimer's disease pathology: pathways between central norepinephrine activity, memory, and neuropsychiatric symptoms.

Authors:  Heidi I L Jacobs; Joost M Riphagen; Inez H G B Ramakers; Frans R J Verhey
Journal:  Mol Psychiatry       Date:  2019-05-28       Impact factor: 15.992

Review 9.  Optimal treatment of Alzheimer's disease psychosis: challenges and solutions.

Authors:  Jeremy Koppel; Blaine S Greenwald
Journal:  Neuropsychiatr Dis Treat       Date:  2014-11-24       Impact factor: 2.570

10.  The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer's disease.

Authors:  Yannick Vermeiren; Debby Van Dam; Tony Aerts; Sebastiaan Engelborghs; Jean-Jacques Martin; Peter P De Deyn
Journal:  Alzheimers Res Ther       Date:  2015-02-11       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.